EBV promotes TCR-T-cell therapy resistance by inducing CD163+M2 macrophage polarization and MMP9 secretion.
Yuanyuan ChenDijun OuyangYan WangQiuzhong PanJingjing ZhaoHao ChenXinyi YangYan TangQijing WangYongqiang LiJia HeJin-Qi YouYingzi LiChi XuYan RenSisi XieSong LiJiamin LianDesheng WengTong XiangJian-Chuan XiaPublished in: Journal for immunotherapy of cancer (2024)
MMP9 inhibitors improve TCR-T cell function suppressed by EBV-induced M2 macrophages. TCR-T-cell therapy combined with MMP9 inhibitors was an effective therapeutic strategy for EBV-positive solid tumors.